1
项与 Allogeneic Granulocyte(Shanghai East Hospital) 相关的临床试验Clinical Study of Allogeneic Granulocyte Infusion in the Treatment of Patients With Advanced Cancer
Background & Rationale:
For years, most tumor immunotherapy researches have focused on T cell and natural killer (NK) cell therapies, most of which involve amplification and modification of the patient's immune cells for reinfusion therapy. However, for the treatment of solid tumors, there is currently little breakthrough. Recently, researchers have reported a colony of cancer-resistant mice developed from a single mouse that was immune to multiple lethal cancer cell injections. Further research revealed that such anti-cancer immunity can cause rapid shrinkage or disappearance of the tumors in other cancer-bearing mice. Interestingly, this therapeutic effect is due to the donor granulocytes, instead of T cells or NK cells. Infusion of granulocytes is a classic therapy in treating infection associated with granulocytopenia. Currently, clinical collection of blood components, including isolation of granulocytes, is a mature technique. The infusion of granulocytes is a viable anticancer therapy combining the classic technique and novel anticancer approach. This proposed trial will test whether granulocyte infusions from healthy unrelated donors can be used to treat advanced cancer. In the proposed trial, up to 100 Subjects with advanced cancer can be entered. Each patient will be given a dose of (2.0-5.0)x10^10 granulocytes from a different healthy donor every week over a course of 5 doses. The trial will evaluate the subject's cancer 7, 30, 90 and 180 days after the last infusion.
100 项与 Allogeneic Granulocyte(Shanghai East Hospital) 相关的临床结果
100 项与 Allogeneic Granulocyte(Shanghai East Hospital) 相关的转化医学
100 项与 Allogeneic Granulocyte(Shanghai East Hospital) 相关的专利(医药)
100 项与 Allogeneic Granulocyte(Shanghai East Hospital) 相关的药物交易